267 related articles for article (PubMed ID: 18223351)
1. Analgesic efficacy of controlled-release oxycodone in patients with uterine or ovarian cancer.
Suzuki T; Morishita M; Ito E; Matsuura M; Tanaka R; Saito T
Am J Ther; 2008; 15(1):31-5. PubMed ID: 18223351
[TBL] [Abstract][Full Text] [Related]
2. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
3. Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study.
Portenoy RK; Farrar JT; Backonja MM; Cleeland CS; Yang K; Friedman M; Colucci SV; Richards P
Clin J Pain; 2007 May; 23(4):287-99. PubMed ID: 17449988
[TBL] [Abstract][Full Text] [Related]
4. [Feasibility to treat pediatric cancer pain with analgesics for adults and their efficacy].
Zhen ZJ; Sun XF; Xia Y; Ling JY; Zheng L; Luo WB; Lin H
Ai Zheng; 2007 Aug; 26(8):866-9. PubMed ID: 17697549
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
[TBL] [Abstract][Full Text] [Related]
6. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain.
Hagen NA; Babul N
Cancer; 1997 Apr; 79(7):1428-37. PubMed ID: 9083166
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-naive cancer pain patients, starting with 5 mg tablets.
Koizumi W; Toma H; Watanabe K; Katayama K; Kawahara M; Matsui K; Takiuchi H; Yoshino K; Araki N; Kodama K; Kimura H; Kono I; Hasegawa H; Hatanaka K; Hiraga K; Takeda F
Jpn J Clin Oncol; 2004 Oct; 34(10):608-14. PubMed ID: 15591459
[TBL] [Abstract][Full Text] [Related]
8. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation.
Meissner W; Leyendecker P; Mueller-Lissner S; Nadstawek J; Hopp M; Ruckes C; Wirz S; Fleischer W; Reimer K
Eur J Pain; 2009 Jan; 13(1):56-64. PubMed ID: 18762438
[TBL] [Abstract][Full Text] [Related]
9. Postmarketing surveillance study of OxyContin tablets for relieving moderate to severe cancer pain.
Yu SY;
Oncology; 2008; 74 Suppl 1():46-51. PubMed ID: 18758197
[TBL] [Abstract][Full Text] [Related]
10. Use of oxycodone in polytrauma patients: the "Gemelli" experience.
Franceschi F; Marini M; Ursella S; Carbone L; Candelli M; Pignataro G; Gabrielli M; Santarelli L; Ojetti V; Giupponi B; Fiore V; Barbaro F; De Marco G; Buccelletti F; Mancini F; Roccarina D; Gigante G; Gasbarrini A; Gasbarrini G; Silveri NG
Eur Rev Med Pharmacol Sci; 2008; 12(2):123-6. PubMed ID: 18575163
[TBL] [Abstract][Full Text] [Related]
11. Use of oxycodone controlled-release immediately after NSAIDs: a new approach to obtain good pain control.
Tessaro L; Bandieri E; Costa G; Fornasier G; Iorno V; Pizza C; Pastacaldi G; Micheletto G
Eur Rev Med Pharmacol Sci; 2010 Feb; 14(2):113-21. PubMed ID: 20329570
[TBL] [Abstract][Full Text] [Related]
12. Oral oxycodone: new preparation. No better than oral morphine.
Prescrire Int; 2003 Jun; 12(65):83-4. PubMed ID: 12825566
[TBL] [Abstract][Full Text] [Related]
13. [Conversion ratio between intravenous oxycodone/hydrocotarnine and sustained-release oral oxycodone in patients with cancer pain].
Kokubun H; Nakamura K; Fukawa M; Matoba M; Hoka S; Yago K
Gan To Kagaku Ryoho; 2007 Dec; 34(13):2255-8. PubMed ID: 18079625
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological approach to chronic visceral pain. Focus on oxycodone controlled release: an open multicentric study.
Liguori S; Gottardi M; Micheletto G; Bruno L
Eur Rev Med Pharmacol Sci; 2010 Mar; 14(3):185-90. PubMed ID: 20391956
[TBL] [Abstract][Full Text] [Related]
15. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride.
Etropolski M; Kelly K; Okamoto A; Rauschkolb C
Adv Ther; 2011 May; 28(5):401-17. PubMed ID: 21494892
[TBL] [Abstract][Full Text] [Related]
16. Advancement of opioid analgesia with controlled-release oxycodone.
Levy MH
Eur J Pain; 2001; 5 Suppl A():113-6. PubMed ID: 11798230
[TBL] [Abstract][Full Text] [Related]
17. Controlled-release oxycodone in the treatment of neuropathic pain of nonmalignant and malignant causes.
Ong EC
Oncology; 2008; 74 Suppl 1():72-5. PubMed ID: 18758202
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes during opioid titration following initiation with or conversion to Remoxy®, an extended-release formulation of oxycodone.
Roland CL; Setnik B; Cleveland JM; Brown DA
Postgrad Med; 2011 Jul; 123(4):148-59. PubMed ID: 21680999
[TBL] [Abstract][Full Text] [Related]
19. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
Peniston JH; Gould E
Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetics of controlled-release oxycodone in patients with cancer pain].
Nakamura K; Kokubun H; Komatsu T; Matoba M; Hoka S; Yago K
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1449-53. PubMed ID: 17876144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
